Smaller prospective trials with heterogeneous patient cohorts, including one with choline PET imaging [13], one with PSMA ligand PET imaging [14], and one with sodium fluoride (NA-F) PET imaging [15], showed encouraging results for MDT in oligometastatic prostate cancer. The gene discussed is FOLH1; the disease is prostate cancer.